Download PDF

1. Company Snapshot

1.a. Company Description

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide.The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses.


In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production.It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories.The company was founded in 1870 and is headquartered in Aubagne, France.


Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Show Full description

1.b. Last Insights on DIM

Sartorius Stedim Biotech SA's recent performance was driven by steady revenue growth, with a 10% year-over-year increase in Q4 2024. The company's robust order intake, up 14% year-over-year, suggests a strong demand for its biopharmaceutical equipment and services. Additionally, Sartorius Stedim Biotech's strategic expansions, including its recent investments in the US and Asia, are expected to fuel future growth. Furthermore, the company has announced a €500 million share buyback program, which will reduce the number of outstanding shares and increase earnings per share. This strategic move is expected to benefit shareholders in the long run.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Discover 3 European Stocks Believed To Be Trading Below Intrinsic Value

Oct -02

Source:

Card image cap

European Hidden Value Stocks That Might Be Priced Below Intrinsic Estimates

Sep -02

Source:

Card image cap

Sartorius to invest $3m for minority share in biotech start-up Nanotein

Aug -12

Source:

Card image cap

Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing

Aug -11

Source:

Card image cap

3 European Stocks Estimated At Up To 41.3% Discount To Intrinsic Value

Jul -30

Source:

Card image cap

Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

Jul -29

Source:

Card image cap

Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform

Jul -09

Source:

Card image cap

Sartorius Stedim Biotech SA (SDMHF) Q1 2025 Earnings Call Highlights: Strong Bioprocess Growth ...

Apr -17

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.00%)

6. Segments

Biopharmaceuticals

Expected Growth: 10%

Sartorius Stedim Biotech S.A.'s biopharmaceuticals segment growth is driven by increasing demand for biologics, rising adoption of single-use technologies, and growing outsourcing trends in the biopharmaceutical industry. Additionally, the company's strong product portfolio, strategic acquisitions, and expanding presence in emerging markets contribute to its 10% growth.

7. Detailed Products

Bioreactors

Sartorius Stedim Biotech's bioreactors are designed for cell culture and fermentation applications, offering scalable and flexible solutions for biopharmaceutical development and production.

Fermenters

Sartorius Stedim Biotech's fermenters are designed for microbial fermentation, offering high-performance solutions for bioproduct development and production.

Downstream Processing Equipment

Sartorius Stedim Biotech's downstream processing equipment is designed for the purification and separation of bioproducts, offering scalable and flexible solutions for biopharmaceutical development and production.

Single-Use Systems

Sartorius Stedim Biotech's single-use systems are designed for biopharmaceutical development and production, offering flexible and scalable solutions for cell culture, fermentation, and downstream processing.

Analytics and Testing

Sartorius Stedim Biotech's analytics and testing solutions are designed for the development and production of biopharmaceuticals, offering a range of analytical instruments and services.

Process Development Services

Sartorius Stedim Biotech's process development services are designed to support biopharmaceutical development and production, offering expertise in process development, optimization, and scale-up.

8. Sartorius Stedim Biotech S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Sartorius Stedim Biotech S.A. is medium due to the presence of alternative products and services in the biotechnology industry.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Sartorius Stedim Biotech S.A.'s products and services, which limits the ability of customers to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium due to the presence of multiple suppliers in the market, but Sartorius Stedim Biotech S.A.'s large scale of operations gives it some negotiating power.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the biotechnology industry, leading to a competitive market environment.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 57.64%
Debt Cost 4.83%
Equity Weight 42.36%
Equity Cost 7.14%
WACC 5.81%
Leverage 136.05%

11. Quality Control: Sartorius Stedim Biotech S.A. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
EssilorLuxottica

A-Score: 5.2/10

Value: 0.8

Growth: 5.8

Quality: 6.2

Yield: 3.1

Momentum: 8.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
Coloplast

A-Score: 4.5/10

Value: 1.8

Growth: 4.1

Quality: 6.7

Yield: 5.6

Momentum: 0.0

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Straumann

A-Score: 3.9/10

Value: 0.9

Growth: 5.7

Quality: 8.0

Yield: 3.1

Momentum: 0.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Carl Zeiss Meditec

A-Score: 3.3/10

Value: 3.9

Growth: 5.0

Quality: 5.9

Yield: 1.9

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Sartorius Stedim Biotech

A-Score: 3.0/10

Value: 0.7

Growth: 5.6

Quality: 4.7

Yield: 0.0

Momentum: 4.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Tobii Dynavox

A-Score: 2.6/10

Value: 0.2

Growth: 5.2

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

213.3$

Current Price

213.3$

Potential

-0.00%

Expected Cash-Flows